Victoria Rai
About
Research
Publications
2025
Suppression of ADPKD Alters Epithelial Cell Transcription Program
Rai V, Failli M, Fiusco M, Reyna-Neyra M, Sorrentino N, Onuchic L, Di Bernardo D, Craft J, Caplan M. Suppression of ADPKD Alters Epithelial Cell Transcription Program. Journal Of The American Society Of Nephrology 2025, 36: 10.1681/asn.2025htchhnxk. DOI: 10.1681/asn.2025htchhnxk.Peer-Reviewed Original ResearchSuppression of Autosomal Dominant Polycystic Kidney Disease Influences Epithelial Cell Transcription Program
Rai V, Failli M, Fiusco M, Reyna-Neyra A, Onuchic L, di Bernardo D, Craft J, Caplan M. Suppression of Autosomal Dominant Polycystic Kidney Disease Influences Epithelial Cell Transcription Program. Physiology 2025, 40: 0966. DOI: 10.1152/physiol.2025.40.s1.0966.Peer-Reviewed Original ResearchC-terminal tailCystic phenotypeTranscriptional programsAutosomal dominant polycystic kidney diseaseScRNA-seqTranscriptional differencesAmino acid C-terminal tailAcidic C-terminal tailPolycystin-1 proteinCell transcriptional programDifferentiated cell stateEpithelial cellsSingle cell RNA sequencingDoxycycline-inducible mouse modelCell RNA sequencingNovel transcriptsLibrary preparationCell transcriptional profilingChromium technologyPKD1 geneBiological replicatesRNA velocityCDNA synthesisRNA sequencingTranscriptional profiles
2024
Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy
Akiyama S, St-Pierre J, Traboulsi C, Silfen A, Rai V, Rodriguez T, Erondu A, Steinberg J, Shaffer S, Christensen B, Rubin D. Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy. Npj Gut And Liver 2024, 1: 5. DOI: 10.1038/s44355-024-00005-9.Peer-Reviewed Original ResearchHistologic normalizationUlcerative colitisDe-EscalationUC patientsDe-escalation of therapyTherapeutic de-escalationMedian Follow-UpDe-escalation groupProportion of patientsStudy assessed outcomesHistological recurrenceRecurrence rateSingle-centerClinical stabilityTherapeutic changeRemission outcomesFollow-upTherapyPatientsImmunomodulationAminosalicylatesWithdrawalColitisMonthsOutcomesWhen Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease
Systrom H, Rai V, Singh S, Baidoo L, Cheifetz A, Devlin S, Gecse K, Irving P, Kaplan G, Kozuch P, Ullman T, Sparrow M, Melmed G, Siegel C. When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2024, 120: 420-430. PMID: 39008539, DOI: 10.14309/ajg.0000000000002964.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAsymptomatic patientsChanging therapyStable diseaseEndoscopic remissionEndoscopic activityBowel diseaseAsymptomatic inflammatory bowel diseaseRAND/University of California Los Angeles Appropriateness MethodTreat-to-target strategyActive endoscopic diseaseUlcerative colitis patientsCrohn's disease patientsLos Angeles Appropriateness MethodExtensive diseaseDisease extentPatient ageAphthous ulcersRandomized studyEndoscopic diseaseClinical decision-makingColitis patientsAdvanced therapiesTreatment adjustmentAnonymous surveyA Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease
Akiyama S, Cohen N, Ollech J, Traboulsi C, Rodriguez T, Rai V, Glick L, Yi Y, Runde J, Cohen R, Skowron K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae045. PMID: 39347443, PMCID: PMC11438232, DOI: 10.1093/crocol/otae045.Peer-Reviewed Original ResearchModified pouchitis disease activity indexPouchitis Disease Activity IndexInflammatory bowel diseasePouch-related fistulasDisease activity indexEndoscopic phenotypesComparative analysis of clinical symptomsInflammatory phenotypeClinical symptomsFocal inflammationAfferent limbComplete-case analysisBowel diseaseAnalysis of clinical symptomsActivity indexInflammatory bowel disease patientsAssess symptomsComplete-caseIncomplete emptyingPouch bodyNormal pouchEndoscopic findingsDiagnosing pouchitisDiffuse inflammationPerianal symptomsEndoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease
Akiyama S, Ollech J, Cohen N, Traboulsi C, Rai V, Glick L, Yi Y, Runde J, Cohen R, Olortegui K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2024, 31: 63-71. PMID: 38916136, PMCID: PMC11700886, DOI: 10.1093/ibd/izae106.Peer-Reviewed Original ResearchPouch-related fistulasInflammatory bowel diseaseNormal pouchDiffuse inflammationFocal inflammationAfferent limbBowel diseaseAssociated with favorable outcomesIleal pouch-anal anastomosisPouch-anal anastomosisPouch lossEndoscopic phenotypesIleostomy takedownFavorable outcomePouch inflammationPouch excisionPouch phenotypesPrimary phenotypeFistulaEndoscopic classificationInflammationPatientsPouch bodyCuffitisPhenotypic transitionRecommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials
Siegel C, Rai V, Outtier A, Vermeire S, Law C, Sands B, Abdulhamid A, Gearry R, McGuire J, Lindsay J, Panaccione R, Schweistein H, Dotan I, Scarallo L, Griffiths A, Dubinsky M. Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials. Journal Of Crohn's And Colitis 2024, 18: jjae097. PMID: 38908002, DOI: 10.1093/ecco-jcc/jjae097.Peer-Reviewed Original ResearchTrial recruitmentClinical trial eligibilityTrial eligibilityInflammatory bowel disease specialistsInflammatory bowel diseaseRAND/UCLA Appropriateness MethodClinical trial recruitmentRepresentative patient populationIBD specialistsEligibility criteriaAppropriate methodsEligibilityAnonymous votingPatient populationPrior medicationsComplicated disease phenotypeBaseline studyRecommendationsInternational groupLiterature reviewSpecialistsInflammatory bowel disease clinical trialsBowel diseaseColonoscopyRAND/UCLAIdentification of Early Transcriptional Markers of Autosomal Dominant Polycystic Kidney Disease Cystic Epithelial Cells
Rai V, Failli M, Fiusco M, Reyna-Neyra A, di Bernardo D, Craft J, Caplan M. Identification of Early Transcriptional Markers of Autosomal Dominant Polycystic Kidney Disease Cystic Epithelial Cells. Physiology 2024, 39: 1176. DOI: 10.1152/physiol.2024.39.s1.1176.Peer-Reviewed Original ResearchC-terminal tailAutosomal dominant polycystic kidney diseaseScRNA-seqPolycystin-1 C-terminal tailPolycystin-1 proteinEpithelial cellsSingle cell RNA sequencingTranscriptional signatureCell RNA sequencingLibrary preparationChromium technologyCystic epithelial cellsBiological replicatesPolycystin-1Amino acid portionTranscriptional programsCDNA synthesisRNA sequencingTranscriptional changesTranscriptional profilesCyst epithelial cellsExpression of multiple markersMonogenic diseasesDominant polycystic kidney diseaseProtein expression levelsCHANGING THERAPY TO ACHIEVE ENDOSCOPIC HEALING IN ASYMPTOMATIC PATIENTS WITH IBD: WHEN IS PERFECT THE ENEMY OF GOOD?
Systrom H, Rai V, Singh S, Baidoo L, Cheifetz A, Devlin S, Gecse K, Irving P, Kaplan G, Kozuch P, Ullman T, Sparrow M, Melmed G, Siegel C. CHANGING THERAPY TO ACHIEVE ENDOSCOPIC HEALING IN ASYMPTOMATIC PATIENTS WITH IBD: WHEN IS PERFECT THE ENEMY OF GOOD? Gastroenterology 2024, 166: s115-s116. DOI: 10.1053/j.gastro.2023.11.264.Peer-Reviewed Original ResearchCHANGING THERAPY TO ACHIEVE ENDOSCOPIC HEALING IN ASYMPTOMATIC PATIENTS WITH IBD: WHEN IS PERFECT THE ENEMY OF GOOD?
Systrom H, Rai V, Singh S, Baidoo L, Cheifetz A, Devlin S, Gecse K, Irving P, Kaplan G, Kozuch P, Ullman T, Sparrow M, Melmed G, Siegel C. CHANGING THERAPY TO ACHIEVE ENDOSCOPIC HEALING IN ASYMPTOMATIC PATIENTS WITH IBD: WHEN IS PERFECT THE ENEMY OF GOOD? Inflammatory Bowel Diseases 2024, 30: s83-s83. DOI: 10.1093/ibd/izae020.180.Peer-Reviewed Original ResearchInflammatory bowel diseaseEndoscopic healingAsymptomatic patientsChanging therapyScenarios of patientsCrohn's diseaseUlcerative colitisInflammatory bowel disease specialistsTreat-to-target strategyAsymptomatic IBD patientsPatients aged >Treatment decision-makingStable diseaseEndoscopic improvementClinical remissionExtensive diseaseAnti-TNFEndoscopic progressionDisease extentAphthous ulcersEndoscopic inflammationRandomized studyCurrent therapiesEndoscopic diseaseClinical decision-making